The DOI matches its Crossref record; 34 of the 34 references it cites were found in a registry or an index.
Incidence and Predictors of Severe Liver Fibrosis in Human Immunodeficiency Virus–Infected Patients with Chronic Hepatitis C: A European Collaborative Study
Open accessAbstract
A study was performed in 10 European health care centers in which 914 patients coinfected with hepatitis C virus (HCV) and human immunodeficiency virus (HIV) who had elevated serum alanine aminotransferase (ALT) levels underwent liver biopsy during the period of 1992 through 2002. Overall, the METAVIR liver fibrosis stage was F0 in 10% of patients, F1 in 33%, F2 in 22%, F3 in 22%, and F4 in 13%. Predictors of severe liver fibrosis (METAVIR stage, F3 or F4) in multivariate analysis were age of >35 years (odds ratio [OR], 2.95; 95% confidence interval [CI], 2.08-4.18), alcohol consumption of >50 g/day (OR, 1.61; 95% CI, 1.1-2.35), and CD4+ T cell count of <500 cells/mm3 (OR, 1.43; 95% CI, 1.03-1.98). Forty-six percent of patients aged >40 years had severe liver fibrosis, compared with 15% of subjects aged <30 years. The use of antiretroviral therapy was not associated with the severity of liver fibrosis. In summary, severe liver fibrosis is frequently found in HCV-HIV-coinfected patients with elevated serum ALT levels, and its severity increases significantly with age. The rate of complications due to end-stage liver disease will inevitably increase in this population, for whom anti-HCV therapy should be considered a priority.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Palella, F. J., Delaney, K. M., Moorman, A. C., Loveless, M. O., Fuhrer, J., Satten, G. A., Aschman, D. J., & Holmberg, S. D. (1998) · New England Journal of Medicine · doi:10.1056/nejm199803263381301 · Cited by 9,405
Peginterferon Alfa-2a plus Ribavirin for Chronic Hepatitis C Virus Infection
Fried, M. W., Shiffman, M. L., Reddy, K. R., Smith, C., Marinos, G., Gonçales, F. L., Häussinger, D., Diago, M., Carosi, G., Dhumeaux, D., et al. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa020047 · Cited by 6,389
Manns, M. P., McHutchison, J. G., Gordon, S. C., Rustgi, V. K., Shiffman, M., Reindollar, R., Goodman, Z. D., Koury, K., Ling, M.-H., & Albrecht, J. K. (2001) · The Lancet · doi:10.1016/s0140-6736(01)06102-5 · Cited by 6,029
An Algorithm for the Grading of Activity in Chronic Hepatitis C
Bedossa, P., & Poynard, T. (1996) · Hepatology · doi:10.1002/hep.510240201 · Cited by 4,088
Regier, D. A. (1990) · JAMA · doi:10.1001/jama.1990.03450190043026 · Cited by 3,962
Natural history of liver fibrosis progression in patients with chronic hepatitis C
Poynard, T., Bedossa, P., & Opolon, P. (1997) · The Lancet · doi:10.1016/s0140-6736(96)07642-8 · Cited by 3,011
Bedossa, P. (1994) · Hepatology · doi:10.1002/hep.1840200104 · Cited by 2,003
Surveillance for asthma--United States, 1980-1999.
Mannino, D. M., Homa, D. M., Akinbami, L. J., Moorman, J. E., Gwynn, C., & Redd, S. C. (2002) · PubMed · Cited by 1,699
Liver fibrosis progression in human immunodeficiency virus and hepatitis C virus coinfected patients
Benhamou, Y., Bochet, M., Di Martino, V., Charlotte, F., Azria, F., Coutellier, A., Vidaud, M., Bricaire, F., Opolon, P., Katlama, C., et al. (1999) · Hepatology · doi:10.1002/hep.510300409 · Cited by 1,219
Self-citation(1998) · PsycEXTRA Dataset · doi:10.1037/e547602006-001 · Cited by 1,213
Identification of chronic hepatitis C patients without hepatic fibrosis by a simple predictive model
Forns, X. (2002) · Hepatology · doi:10.1016/s0270-9139(02)00107-6 · Cited by 1,125
Bica, I., McGovern, B., Dhar, R., Stone, D., McGowan, K., Scheib, R., & Snydman, D. R. (2001) · Clinical Infectious Diseases · doi:10.1086/318501 · Cited by 974
Graham, C. S., Baden, L. R., Yu, E., Mrus, J. M., Carnie, J., Heeren, T., & Koziel, M. J. (2001) · Clinical Infectious Diseases · doi:10.1086/321909 · Cited by 974
Sulkowski, M. S. (2000) · JAMA · doi:10.1001/jama.283.1.74 · Cited by 950
Rates and risk factors of liver fibrosis progression in patients with chronic hepatitis c
Poynard, T., Ratziu, V., Charlotte, F., Goodman, Z., McHutchison, J., & Albrecht, J. (2001) · Journal of Hepatology · doi:10.1016/s0168-8278(00)00097-0 · Cited by 749
Soto, B., Sánchez-Quijano, A., Rodrigo, L., Olmo, J. A. D., García-Bengoechea, M., Hernández-Quero, J., Rey, C., Abad, M. A., Rodríguez, M., Sales Gilabert, M., et al. (1997) · Journal of Hepatology · doi:10.1016/s0168-8278(97)80001-3 · Cited by 701
Armstrong, G. L., Alter, M. J., McQuillan, G. M., & Margolis, H. S. (2000) · Hepatology · doi:10.1002/hep.510310332 · Cited by 523
A comparison of fibrosis progression in chronic liver diseases
Poynard, T., Mathurin, P., Lai, C.-L., Guyader, D., Poupon, R., Tainturier, M.-H., Myers, R. P., Muntenau, M., Ratziu, V., Manns, M., et al. (2003) · Journal of Hepatology · doi:10.1016/s0168-8278(02)00413-0 · Cited by 474
Soriano, V., Sulkowski, M., Bergin, C., Hatzakis, A., Cacoub, P., Katlama, C., Cargnel, A., Mauss, S., Dieterich, D., Moreno, S., et al. (2002) · AIDS · doi:10.1097/00002030-200204120-00001 · Cited by 444
Self-citationBenhamou, Y., Di Martino, V., Bochet, M., Colombet, G., Thibault, V., Liou, A., Katlama, C., & Poynard, T. (2001) · Hepatology · doi:10.1053/jhep.2001.26517 · Cited by 424
Self-citationProgression of fibrosis in chronic hepatitis C
Ghany, M. G., Kleiner, D. E., Alter, H., Doo, E., Khokar, F., Promrat, K., Herion, D., Park, Y., Liang, T. J., & Hoofnagle, J. H. (2003) · Gastroenterology · doi:10.1053/gast.2003.50018 · Cited by 403
Natural history of hepatitis C
Alberti, A., Chemello, L., & Benvegnù, L. (1999) · Journal of Hepatology · doi:10.1016/s0168-8278(99)80369-9 · Cited by 367
Di Martino, V., Rufat, P., Boyer, N., Renard, P., Degos, F., Martinot-Peignoux, M., Matheron, S., Le Moing, V., Vachon, F., Degott, C., et al. (2001) · Hepatology · doi:10.1053/jhep.2001.29201 · Cited by 335
Poynard, T., & Bedossa, P. (1997) · Journal of Viral Hepatitis · doi:10.1046/j.1365-2893.1997.00141.x · Cited by 277
Risk Factors for Severe Hepatic Injury After Introduction of Highly Active Antiretroviral Therapy
Núñez, M., Lana, R., Mendoza, J. L., Martín-Carbonero, L., & Soriano, V. (2001) · Journal of Acquired Immune Deficiency Syndromes · doi:10.1097/00042560-200108150-00002 · Cited by 251
Self-citationMartinez‐Sierra, C., Arizcorreta, A., Diaz, F., Roldan, R., Martin‐Herrera, L., Perez‐Guzman, E., & Giron‐Gonzalez, J. A. (2003) · Clinical Infectious Diseases · doi:10.1086/367643 · Cited by 244
Self-citationMortality for Liver Disease in Patients With HIV Infection: A Cohort Study
Puoti, M., Spinetti, A., Ghezzi, A., Donato, F., Zaltron, S., Putzolu, V., Quiros-Roldan, E., Zanini, B., Casari, S., & Carosi, G. (2000) · Journal of Acquired Immune Deficiency Syndromes · doi:10.1097/00042560-200007010-00003 · Cited by 224
Self-citationMartín-Carbonero, L., Soriano, V., Valencia, E., García-Samaniego, J., López, M., & González-Lahoz, J. (2001) · AIDS Research and Human Retroviruses · doi:10.1089/08892220152644160 · Cited by 221
Self-citationPegylated IFN-α2b plus ribavirin as therapy for chronic hepatitis C in HIV-infected patients
Pérez-Olmeda, M., Núñez, M., Romero, M., González, J., Castro, A., Arribas, J. R., Pedreira, J., Barreiro, P., García-Samaniego, J., Martín-Carbonero, L., et al. (2003) · AIDS · doi:10.1097/00002030-200305020-00011 · Cited by 200
Self-citationPuoti, M., Bonacini, M., Spinetti, A., Putzolu, V., Govindarajan, S., Zaltron, S., Favret, M., Callea, F., Gargiulo, F., Donato, F., et al. (2001) · The Journal of Infectious Diseases · doi:10.1086/317644 · Cited by 195
Self-citationRagni, M. V., & Belle, S. H. (2001) · The Journal of Infectious Diseases · doi:10.1086/319273 · Cited by 194
Vento, S., Garofano, T., Renzini, C., Casali, F., Ferraro, T., & Concia, E. (1998) · PubMed · Cited by 168
Chung, R. T., Evans, S. R., Yang, Y., Theodore, D., Valdez, H., Clark, R., Shikuma, C., Nevin, T., & Sherman, K. E. (2002) · AIDS · doi:10.1097/00002030-200209270-00008 · Cited by 160
Hepatotoxicity of antiretroviral therapy.
Kontorinis, N., & Dieterich, D. T. (2003) · PubMed · Cited by 112
Cited by
Sterling, R. K., Lissen, E., Clumeck, N., Sola, R., Correa, M. C., Montaner, J., S. Sulkowski, M., Torriani, F. J., Dieterich, D. T., Thomas, D. L., et al. (2006) · Hepatology · doi:10.1002/hep.21178 · Cited by 5,021
Gazzard, B., & on behalf of the BHIVA Treatment Guidelines Writing Group (2008) · HIV Medicine · doi:10.1111/j.1468-1293.2008.00636.x · Cited by 1,089
Xiao, G., Zhu, S., Xiao, X., Yan, L., Yang, J., & Wu, G. (2017) · Hepatology · doi:10.1002/hep.29302 · Cited by 895
Immune restoration disease after antiretroviral therapy
French, M. A., Price, P., & Stone, S. F. (2004) · AIDS · doi:10.1097/01.aids.0000131375.21070.06 · Cited by 651
Thein, H.-H., Yi, Q., Dore, G. J., & Krahn, M. D. (2008) · AIDS · doi:10.1097/qad.0b013e32830e6d51 · Cited by 409
Metadata
- Authors
- Martin‐Carbonero, L., Benhamou, Y., Puoti, M., Berenguer, J., Mallolas, J., Quereda, C., Arizcorreta, A., Gonzalez, A., Rockstroh, J., Asensi, V., Miralles, P., Laguno, M., Moreno, L., Giron, J. A., Vogel, M., Garcia‐Samaniego, J., Nunez, M., Romero, M., Moreno, S., de la Cruz, J. J., & Soriano, V.
- Venue
- Clinical Infectious Diseases
- Publisher
- Oxford University Press (OUP)
- Published
- 2004-01
- Volume
- 38
- Issue
- 1
- Pages
- 128-133
- ISSN
- 1058-4838 (ISSN-L)
- 1537-6591
- OpenAlex
- W2145920352
- Cited by
- 272
- References
- 34
- FWCI
- 15.90
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.